Shares of Alignment Healthcare, Inc. (ALHC) surged 9.23% in pre-market trading on Friday, following the company's impressive third-quarter earnings report and a series of analyst upgrades. The healthcare services provider demonstrated robust financial performance, surpassing market expectations and prompting renewed investor confidence.

Alignment Healthcare's Q3 2025 financial results, released on Thursday, exceeded analysts' projections, showcasing the company's strong growth trajectory. In response to the positive earnings surprise, several prominent Wall Street firms raised their price targets for ALHC stock. Leerink Partners increased its target from $20 to $23, while Stephens adjusted its forecast from $20 to $24. UBS and KeyBanc also revised their outlooks upward, with UBS raising its target to $18 from $17 and KeyBanc maintaining a Buy rating with a $21 price target.

The bullish sentiment surrounding Alignment Healthcare stems from its solid financial performance and promising growth prospects in the competitive healthcare sector. As the company continues to expand its market presence and improve its service offerings, investors appear increasingly optimistic about its long-term potential. The pre-market stock surge reflects growing confidence in Alignment Healthcare's business model and its ability to capitalize on opportunities in the evolving healthcare landscape.